Factors influencing immunodominance hierarchies in TCD8+-mediated antiviral responses

Expert Review of Clinical Immunology

Volumn 2, Issue 1, 2006, Pages 135-147

  Irvine, Kari R ^a   Bennink, Jack R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; HLA A2 ANTIGEN; HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; EPSTEIN BARR VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACROPHAGE; MEMORY T LYMPHOCYTE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS LOAD;

EID: 33748517435     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.1.135     Document Type: Review

References (116)

1. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27, 51-177 (1979).
2. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Ann. Rev. Immunol. 17, 51-88 (1999).
3. van der Most RG, Murali-Krishna K, Lanier JG et al. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 315(1), 93-102 (2003).
4. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187(10), 1647-1657 (1998).
5. + T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 198(3), 399-410 (2003).
6. Phillips RE, Rowland-Jones S, Nixon DF et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354(6353), 453-459 (1991).
7. Koup RA. Virus escape from CTL recognition. J. Exp. Med. 180(3), 779-782 (1994).
8. Allen TM, O'Connor DH, Jing P et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407(6802), 386-390 (2000).
9. Goulder PJ, Brander C, Tang Y et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412(6844), 334-338 (2001).
10. Rimmelzwaan GF, Boon AC, Voeten JT, Berkhoff EG, Fouchier RA, Osterhaus AD. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res. 103(1-2), 97-100 (2004).
11. Price DA, West SM, Betts MR et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21(6), 793-803 (2004).
12. Lewicki HA, von Herrath MG, Evans CF, Whitton JL, Oldstone MB. CTL escape viral variants. II. Biologic activity in vivo. Virology 211(2), 443-450 (1995).
13. Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12(1), 83-93 (2000).
14. Tynan FE, Burrows SR, Buckle AM et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nature Immunol. 6(11), 1114-1122 (2005).
15. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351(6324), 290-296 (1991).
16. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21(11), 2891-2894 (1991).
17. Engelhard VH. Structure of peptides associated with MHC class I molecules. Curr. Opin. Immunol. 6(1), 13-23 (1994).
18. Sette A, Sidney J, del Guercio MF et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31(11), 813-822 (1994).
19. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol. Res. 14(1), 34-57 (1995).
20. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4), 213-219 (1999).
21. Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10(4), 478-482 (1998).
22. Sette A, Vitiello A, Reherman B et al.The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153 (12), 5586-5592 (1994).
23. + T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med. 193(11), 1319-1326 (2001).
24. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft versus host disease. J. Exp. Med. 179(4), 1155-1161 (1994).
25. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argaet VP. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med. 182(6), 1703-1715 (1995).
26. Selin LK, Vergilis K, Welsh RM, Nahill SR. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J. Exp. Med. 183(6), 2489-2499 (1996).
27. Blattman JN, Antia R, Sourdive DJ et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 195(5), 657-664 (2002).
28. Kjer-Nielsen L, Clements CS, Purcell AW et al. A structural basis for the selection of dominant αβ T cell receptors in antiviral Immunity 18(1), 53-64 (2003).
29. Borg NA, Ely LK, Beddoe T et al. The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition. Nature Immunol. 6(2), 171-180 (2005).
30. Stewart-Jones GB, McMichael AJ, Bell JI, Stuart DI, Jones EY. A structural basis for immunodominant human T cell receptor recognition. Nature Immunol. 4(7), 657-663 (2003).
31. Aebischer T, Oehen S, Hengartner H. Preferential usage of V α4 and Vβ 10 T cell receptor genes by lymphocytic choriomeningitis virus glycoprotein-specific H-2Db-restricted cytotoxic T cells. Eur. J. Immunol. 20(3), 523-531 (1990).
32. Deckhut AM, Allan W, McMickle A et al. Prominent usage of Vβ 8.3 T cells in the H-2Db-restricted response to an influenza A virus nucleoprotein epitope. J. Immunol. 151(5), 2658-2666 (1993).
33. Argaet VP, Schmidt CW, Burrows SR et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180(6), 2335-2340 (1994).
34. Kedzierska K, Turner SJ, Doherty PC. Conserved T cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope. Proc. Natl Acad. Sci. USA 101(14), 4942-4947 (2004).
35. Turner SJ, Diaz G, Cross R, Doherty PC. Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity 18(4), 549-559 (2003).
36. Turner SJ, Kedzierska K, Komodromou H et al. Lack of prominent peptide-major histocompatibility complex features limits repertoire diversity in virus-specific CD8+ T cell populations. Nature Immunol. 6(4), 382-389 (2005).
37. + T cell responses. J. Immunol. 166(7), 4627-4633 (2001).
38. + T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J. Virol. 78(4), 1751-1762 (2004).
39. + T cells during negative selection results in an altered antiviral T cell hierarchy. J. Immunol. 170(3), 1231-1239 (2003).
40. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93(9), 4102-4107 (1996).
41. + T cell memory in response to low, high, and excessive levels of epitope. J. Immunol. 168(9), 4455-4461 (2002).
42. + T cell responses: correlation of cytokine profile and TCR avidity. J. Immunol. 172(9), 5553-5560 (2004).
43. Mullbacher A, Lobigs M, Yewdell JW, Bennink JR, Tha HR, Blanden RV. High peptide affinity for MHC class I does not correlate with immunodominance. Scand. J. Immunol. 50(4), 420-426 (1999).
44. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Ann. Rev. Immunol. 11, 213-244 (1993).
45. Crotzer VL, Christian RE, Brooks JM et al. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J. Immunol. 164 (12), 6120-6129 (2000).
46. Hunt DF, Henderson RA, Shabanowitz J et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255(5049), 1261-1263 (1992).
47. Restifo NP, Bacik I, Irvine KR et al. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154(9), 4414-4422 (1995).
48. Anton LC, Yewdell JW, Bennink JR. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J. Immunol. 158(6), 2535-2542 (1997).
49. Falk K, Rotzschke O, Deres K, Metzger J, Jung G, Rammensee HG. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174(2), 425-434 (1991).
50. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404(6779), 770-774 (2000).
51. Niedermann G, Butz S, Ihlenfeldt HG et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2(3), 289-299 (1995).
52. Lopez D, Del Val M. Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. J. Immunol. 159(12), 5769-5772 (1997).
53. Neisig A, Roelse J, Sijts AJ et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J. Immunol. 154(3), 1273-1279 (1995).
54. Wright CA, Kozik P, Zacharias M, Springer S. Tapasin and other chaperones models of the MHC class I loading complex. Biol. Chem. 385(9), 763-778 (2004).
55. Momburg F, Tan P. Tapasin-the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol. Immunol. 39(3-4), 217-233 (2002).
56. Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9-26 (2004).
57. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425(6956), 397-402 (2003).
58. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl Acad. Sci. USA 100(22), 12889-12894 (2003).
59. Houde M, Bertholet S, Gagnon E et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 425(6956), 402-406 (2003).
60. Probst HC, Van Den BM. Priming of CTLs by lymphocytic choriomeningitis virus depends on dendritic cells. J. Immunol. 174(7), 3920-3924 (2005).
61. Zammit DJ, Cauley LS, Pham QM, Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection Immunity 22(5), 561-570 (2005).
62. + dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J. Immunol. 175(1), 196-200 (2005).
63. + dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172(4), 1996-2000 (2004).
64. + T cells by infected dendritic cells in vivo. Nature Immunol. 3(3), 265-271 (2002).
65. Sumen C, Mempel TR, Mazo IB, von Andrian UH. Intravital microscopy: visualizing immunity in context. Immunity 21(3), 315-329 (2004).
66. + T cells by exogenous cell-associated antigens. Immunity 17(2), 211-220 (2002).
67. + T-cell responses to influenza virus. J. Virol. 76(20), 10332-10337 (2002).
68. Bachmann MF, Gallimore A, Linkert S et al. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J. Exp. Med. 189(10), 1521-1530 (1999).
69. Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH, Watts TH. A switch in costimulation from CD28 to 4-1 BB during primary versus secondary CD8 T cell response to influenza in vivo. J. Immunol. 172(2), 981-988 (2004).
70. Dawicki W, Watts TH. Expression and function of 4-1 BB during CD4 versus CD8 T cell responses in vivo. Eur. J. Immunol. 34(3), 743-751 (2004).
71. + T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J. Immunol. 173(8), 5021-5027 (2004).
72. + T-cell response is much less apparent following secondary challenge. J. Virol. 74(8), 3486-3493 (2000).
73. Oseroff C, Kos F, Bui HH et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl Acad. Sci. USA 102(39), 13980-13985 (2005).
74. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 201(3), 349-360 (2005).
75. Mocarski ES Jr. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol. 6(8), 707-717 (2004).
76. van der Most RG, Concepcion RJ, Oseroff C et al. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J. Virol. 71(7), 5110-5114 (1997).
77. + T cell epitopes, virus load, and kinetics of primary antiviral CTL response. J. Immunol. 160(6), 2923-2931 (1998).
78. Wolpert EZ, Grufman P, Sandberg JK, Tegnesjo A, Karre K. Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J. Immunol. 161(9), 4499-4505 (1998).
79. Probst HC, Dumrese T, van den Broek MF. Cutting edge: competition for APC by CTLs of different specificities is not functionally important during induction of antiviral responses. J. Immunol. 168(11), 5387-5391 (2002).
80. Vijh S, Pilip IM, Pamer EG. Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection. Infect. Immun. 67(3), 1303-1309 (1999).
81. Kedl RM, Rees WA, Hildeman DA et al. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192(8), 1105-1113 (2000).
82. Probst HC, Tschannen K, Gallimore A et al. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 171(10), 5415-5422 (2003).
83. + T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J. Immunol. 174(6), 3344-3351 (2005).
84. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J. Immunol. 172(7), 4204-4214 (2004).
85. + T-cell immune responses during chronic viral infection. J. Virol. 78(7), 3578-3600 (2004).
86. Tewari K, Sacha J, Gao X, Suresh M. Effect of chronic viral infection on epitope selection, cytokine production, and surface phenotype of CD8 T cells and the role of IFN-γ receptor in immune regulation. J. Immunol. 172(3), 1491-1500 (2004).
87. Fuller MJ, Zajac AJ. Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 170(1), 477-486 (2003).
88. Evans DT, Piekarczyk MS, Allen TM et al. Immunodominance of a single CTL epitope in a primate species with limited MHC class I polymorphism. J. Immunol. 159(3), 1374-1382 (1997).
89. + T cell response to influenza A viruses. J. Immunol. 165(5), 2404-2409 (2000).
90. Firat H, Garcia-Pons F, Tourdot S et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 29(10), 3112-3121 (1999).
91. Pasquetto V, Bui HH, Giannino R et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J. Immunol. 175(8), 5504-5515 (2005).
92. Selin LK, Lin MY, Kraemer KA et al. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11(6), 733-742 (1999).
93. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J. Virol. 75(23), 11392-11400 (2001).
94. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nature Immunol. 3(7), 627-634 (2002).
95. Hohn H, Kortsik C, Tully G et al. Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and cross-reactivity to a peptide from HIVenv gp120. Eur. J. Immunol. 33(6), 1613-1623 (2003).
96. + T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202(5), 673-685 (2005).
97. + T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. Trends Immunol. 26(3), 166-171 (2005).
98. Houssaint E, Saulquin X, Scotet E, Bonneville M. Immunodominant CD8 T cell response to Epstein-Barr virus. Biomed. Pharmacother. 55(7), 373-380 (2001).
99. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Ann. Rev. Immunol. 15, 405-431 (1997).
100. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol. 61(5), 438-452 (2000).
101. + T cells in vivo: the key to rational vaccine design. Ann. Rev. Immunol. 23, 651-682 (2005).
102. + T cell vaccine design. Expert. Opin. Biol. Ther. 5(2), 263-271 (2005).
103. Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15(4), 461-470 (2003).
104. Lipford GB, Bauer S, Wagner H, Heeg K Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84(2), 298-303 (1995).
105. Pogue RR, Eron J, Frelinger JA, Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl Acad. Sci. USA 92(18), 8166-8170 (1995).
106. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57(20), 4570-4577 (1997).
107. Peters B, Sidney J, Bourne P et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS. Biol. 3(3), e91 (2005).
108. Perkins DL, Berriz G, Kamradt T, Smith JA, Gefter ML. Immunodominance: intramolecular competition between T cell epitopes. J. Immunol. 146(7), 2137-2144 (1991).
109. Palmowski MJ, Choi EM, Hermans IF et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168(9), 4391-4398 (2002).
110. + T-cell responses is dramatically modified by DNA immunization and is regulated by γ interferon. J. Virol. 76(9), 4251-4259 (2002).
111. di Marzo V, Arnott D, Barnaba V et al. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus Type 1-infected subjects. J. Exp. Med. 183(6), 2509-2516 (1996).
112. Hickman HD, Luis AD, Bardet W et al. Cutting edge: class I presentation of host peptides following HIV infection. J. Immunol. 171(1), 22-26 (2003).
113. Herberts CA, van Gaans-van den Brink, van der HE et al. Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. Hum. Immunol. 64(1), 44-55 (2003).
114. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/ boost regimens that use two different vectors. J. Natl Cancer Inst. 89(21), 1595-1601 (1997).
115. Matano T, Kobayashi M, Igarashi H et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199(12), 1709-1718 (2004).
116. + T cell cross-priming via transfer of proteasome substrates. Science 304(5675), 1318-1321 (2004).